San Diego Zoo Wildlife Alliance's Frozen Zoo® at 50: A Blueprint for Global Conservation
SAN DIEGO, May 15, 2025 /PRNewswire/ -- Fifty years ago, San Diego Zoo Wildlife Alliance's Frozen Zoo® began preserving living genetic material, long before scientists knew how it might be used. Today this legacy, visionary for its era, is shaping innovative conservation strategies to safeguard wildlife and serves as the foundational blueprint for a crisis that reaches every corner of our planet—the biodiversity crisis.
The Frozen Zoo is the world's first large-scale, systematic cryogenic (frozen) biological bank dedicated to preserving living cells and reproductive material from wildlife—and remains the largest and most diverse collection of its kind. Building on this vital resource, San Diego Zoo Wildlife Alliance commits to leading the biodiversity banking of all endangered species globally by 2075.
"Species are vanishing at astonishing rates," said Megan Owen, Ph.D., vice president of wildlife conservation science, San Diego Zoo Wildlife Alliance. "By some estimates, Earth loses more than 100 species every day due to mounting environmental and human-driven pressures. While we are advancing technologies to safeguard biodiversity, we recognize that nature itself remains the most powerful biodiversity bank there is—and that biobanking is a unique tool we must develop and use to protect life on Earth, complementing habitat and species protections."
San Diego Zoo Wildlife Alliance is now leading an ambitious global initiative to make biodiversity banking—the preservation of genetic material in many forms—a tool for species conservation worldwide. As part of this initiative, San Diego Zoo Wildlife Alliance, in collaboration with the International Union for Conservation of Nature (IUCN) Species Survival Commission and the Animal Biobanking for Conservation Specialist Group, established the Center for Species Survival (CSS) Biodiversity Biobanking, where the organization's expertise, the largest global network of species expert volunteers, and CSS staff members converge to develop best practices to guide biobanking efforts on all continents.
"We are investing in partnerships to develop biodiversity banking at a scale that matches the challenge of the biodiversity crisis," said Marlys Houck, curator of the Frozen Zoo. "We have collected irreplaceable genetic biodiversity, which is key to species resilience in the face of environmental change. It's vital to keep this effort going and support capacity enhancement worldwide, because the species we bank today could be the key to restoring ecosystems tomorrow."
This global effort focuses not just on mammals, but also on amphibians, reptiles, birds, plant life, marine organisms and invertebrate species that are critical to ecosystem health.
Efforts are emerging around the globe:
Kenya: San Diego Zoo Wildlife Alliance is supporting the construction of a national biobanking repository and increasing biobanking capacity in an area that tackles wildlife challenges on the ground every day.
Vietnam: San Diego Zoo Wildlife Alliance is partnering to enhance expertise through on-site biobanking training in one of the world's richest biodiversity hotspots.
Peru: A strategic framework is being developed to biobank species at field sites on both sides of the Andes Mountains.
Hawai'i: Community-led conservation is informing culturally grounded strategies to biobank the Islands' irreplaceable and rapidly disappearing species.
This work spans marine, forest, and desert ecosystems, aiming to protect keystone species like the sunflower sea star—an organism vital to the coastal kelp forest ecosystem—and help conserve the world's most endangered animals, such as the northern white rhino and the California condor. It also extends to Hawaiian forest birds and native plants, with San Diego Zoo Wildlife Alliance at the forefront of cryopreserving kelp, oaks and other foundational species.
"Through our expertise, training and collaboration, San Diego Zoo Wildlife Alliance is facilitating the development of a worldwide network that will accelerate and scale the use of biomaterials for wildlife conservation—because protecting wildlife helps fortify the interconnected, delicate web of life we all depend on," said Owen.
Due to the foresight of Frozen Zoo founder Kurt Benirschke, M.D., living cell lines from over 11,500 individuals representing 1,337 species are banked—almost twice the number of animals currently living at the San Diego Zoo and San Diego Zoo Safari Park combined. Stored in liquid nitrogen at minus 320 degrees Fahrenheit, the collection includes living cells, embryos and gametes from mammals, birds, reptiles, amphibians and fish.
"For the past half a century, we have been preparing to meet this moment," said Houck. "And now, we are stepping into a doorway of limitless possibilities, and the work we do today—along with our allies—will shape the next 50 years and beyond."
The Frozen Zoo is one of six unique San Diego Zoo Wildlife Alliance biobanking collections that make up its Wildlife Biodiversity Bank. Other collections include the Tissue and DNA Bank, Native Plant Gene Bank, Pathology Archive, Clinical Repository, and Wildlife Artifacts. Together these collections offer a variety of approaches to preserving biodiversity.
Benirschke joined the San Diego Zoo's research committee in 1970, and in 1975, his forward-thinking efforts founded San Diego Zoo Wildlife Alliance's Center for Reproduction of Endangered Species (CRES), now known as the conservation research program, as well as the Frozen Zoo. After he retired from his director role in 1986, he joined the organization's board of trustees, serving as president from 1998-2000. Benirschke passed on September 10, 2018, at 94 years old. His legacy lives on and continues to shape global conservation efforts today.
To learn more, explore partnership opportunities, or support this mission, please visit sdzwa.org/frozenzoo50.
About San Diego Zoo Wildlife AllianceSan Diego Zoo Wildlife Alliance, a nonprofit conservation leader, inspires passion for nature and collaboration for a healthier world. The Alliance supports innovative conservation science through global partnerships and groundbreaking efforts at the world-famous San Diego Zoo and San Diego Zoo Safari Park, both leading zoological institutions and accredited botanical gardens. Through wildlife care expertise, cutting-edge science and continued collaboration, more than 44 endangered species have been reintroduced to native habitats. The Alliance reaches over 1 billion people annually through its two conservation parks and media channels in 170 countries, including San Diego Zoo Wildlife Explorers television, available in children's hospitals across 14 countries. Wildlife Allies—members, donors and guests—make success possible.
CONTACT:
San Diego Zoo Wildlife AlliancePublic Relations619-685-3291sdzwa.org
View original content to download multimedia:https://www.prnewswire.com/news-releases/san-diego-zoo-wildlife-alliances-frozen-zoo-at-50-a-blueprint-for-global-conservation-302456396.html
SOURCE San Diego Zoo Wildlife Alliance
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
DualityBio's Next-Generation HER3 ADC DB-1310 Granted FDA Fast Track Designation
SHANGHAI, July 21, 2025 /PRNewswire/ -- DualityBio (HKEX Stock Code: announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to its next-generation HER3-targeting antibody-drug conjugate (ADC) DB-1310. This designation is for the treatment of adult patients with advanced, unresectable or metastatic nonsquamous non-small cell lung cancer (nsqNSCLC) with an EGFR exon 19 deletion or L858R mutation with disease progression on or after treatment with a third-generation EGFR tyrosine kinase inhibitor (TKI) and platinum-based chemotherapy. DB-1310 is a novel ADC targeting HER3 developed using DualityBio's proprietary DITAC platform. In June 2025, Dr. Aaron E. Lisberg from the University of California, Los Angeles (UCLA) presented the first-in-human Phase I/IIa clinical trial data (NCT05785741) of DB-1310 in an oral session at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The results demonstrated encouraging efficacy and a manageable safety profile in patients with advanced solid tumors who had failed standard therapies. Dr. Hua Mu, Global Chief Medical Officer of DualityBio, stated: "DB-1310 demonstrated encouraging clinical efficacy and manageable safety in patients with EGFRm nsqNSCLC and multiple solid tumors. It is noteworthy that preclinical investigations of DB-1310 in combination with EGFR TKIs and other anticancer agents have also demonstrated robust synergistic tumor suppression activity. We will spare no effort to accelerate the clinical development of DB-1310 and look forward to its potential, as a next-generation HER3 ADC, to become a novel therapeutic option for a broad population of cancer patients." About DualityBio Duality Biotherapeutics is a clinical-stage biotech company dedicated to the discovery and development of next-generation ADC to treat cancer and autoimmune diseases. DualityBio has successfully built several cutting-edge ADC technology platforms with global intellectual property rights. Leveraging a robust pipeline, DualityBio is conducting multiple global clinical trials across 17 countries, has enrolled over 2,000 patients for multiple clinical-stage ADC candidates. Additionally, DualityBio have established strategic collaborations with global MNCs and leading biotech innovators. As a global ADC powerhouse, DualityBio is developing bispecific ADCs, novel-payload ADCs, and autoimmune ADCs. For more information, please visit View original content to download multimedia: SOURCE Duality Biotherapeutics Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Business Upturn
a day ago
- Business Upturn
Sun Pharma reports positive results from Phase 3 trials for ILUMYA
Sun Pharmaceutical Industries has shared encouraging top-line results from two (Phase 3) clinical trials evaluating its biologic drug tildrakizumab 100 mg, marketed as ILUMYA®, for the treatment of active psoriatic arthritis (PsA). The studies, named INSPIRE-1 and INSPIRE-2, tested ILUMYA over a 24-week period. Patients who received ILUMYA showed significant improvements in symptoms of psoriatic arthritis compared to those who received a placebo. Both trials successfully met their primary goal—a higher proportion of patients treated with ILUMYA achieved ACR20 responses, a standard measure used to assess improvement in joint disease, by Week 24. The results were statistically significant. On the safety front, the drug performed as expected. There were no new safety concerns, and the data remained in line with ILUMYA's existing safety record. The drug is already approved to treat moderate-to-severe plaque psoriasis, and these latest findings suggest it may have potential in addressing PsA as well. However, it's important to note that ILUMYA is not yet approved for psoriatic arthritis, and its use for this indication has not been reviewed or authorized by health regulators. Marek Honczarenko, MD, PhD, Senior Vice President and Head of Global Specialty Development at Sun Pharma, stated, 'We are excited to share that both the INSPIRE-1 and INSPIRE-2 clinical trials have successfully met their primary endpoints. These top-line results reinforce the therapeutic potential of ILUMYA as a treatment option for patients with active psoriatic arthritis. We extend our sincere gratitude to the patients, healthcare professionals and administrators whose contributions made the studies possible. We look forward to sharing the complete clinical data in the near future.' Sun Pharma plans to present the full results from these studies at upcoming medical conferences and publish them in peer-reviewed journals. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at


Newsweek
2 days ago
- Newsweek
'Extremely Severe' Obesity on the Rise in US Children—Study
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Extremely severe obesity among American children has increased more than threefold over the past 15 years, with new research published on the JAMA Network, highlighting disturbing trends in prevalence and related health complications. Researchers analyzed national health data from 2008 to 2023, uncovering a surge in the most severe obesity categories for U.S. children aged 2 to 18 years old. Newsweek has reached out to the authors of the study via email Sunday during non-working hours for further comment. Why It Matters The study comes as the nation faces persistent challenges combating childhood obesity, signaling what authors have called a "public health emergency" with wide-ranging medical and economic consequences for future generations. "The findings underscore the urgent need for public health interventions against pediatric obesity in the U.S.," authors Eliane Munte, Xinlian Zhang, Amit Khurana, and Phillipp Hartmann wrote in the study. The sharp upswing in extremely severe obesity among children raises the risk of developing serious medical conditions—including type 2 diabetes, steatotic liver disease, also known as fatty liver disease (MASLD), metabolic syndrome, and cardiovascular disease. According to the U.S. Centers for Disease Control and Prevention (CDC), as of April 2024, approximately 1 in 5 children—14.7 million—are already classified as obese, with the burden disproportionately affecting racial minorities and lower-income families. Untreated, these complications can persist into adulthood, multiplying risks for chronic disease and shortened life expectancy. What To Know The study evaluated data from 25,847 children and teens, drawing from the National Health and Nutrition Examination Survey (NHANES) between 2008 and 2023. Obesity was categorized using percentiles based on age and sex, and researchers identified a 253 percent relative increase in extremely severe obesity. Adolescents aged 16 to 18 and non-Hispanic Black children were especially affected. According to the CDC, the prevalence of obesity in U.S. children and teens aged 2-19 years increased from 19.46 percent in 2008 to 22.52 percent in 2023. Several factors have fueled the rise in pediatric obesity, including decreased physical activity, increased screen time, and greater access to high-calorie, low-nutrient foods. Researchers noted that these issues intensified during the COVID-19 pandemic, with children experiencing a nearly doubled rate of annual weight gain between 2019 and 2021 compared to prior years. "The monthly rate of BMI increase nearly times faster after the virus appeared," Dr. Alyson Goodman of the CDC said in the British Medical Journal (BMJ) in 2021, highlighting the influence of pandemic-era disruptions. Economic and social disparities also contribute significantly to who is most affected. The CDC reported higher obesity rates among children in families below 130 percent of the federal poverty level around 25 percent, compared with those in wealthier households at 11.5 percent. Unequal access to healthy foods, safe recreational spaces, and adequate medical care also play roles, the CDC said in 2024. The JAMA study found significantly higher odds of children developing MASLD (a fatty liver disease), diabetes or prediabetes, metabolic syndrome, insulin resistance, and early signs of heart disease. Left unchecked, these conditions can lead to cirrhosis, liver cancer, and major cardiovascular events later in life. In 2024, the CDC estimated the annual medical cost of childhood obesity at $1.3 billion, underscoring the seriousness of the crisis. A beam scale is seen in New York on April 3, 2018. A beam scale is seen in New York on April 3, 2018. AP Photo/Patrick Sison, File What People Are Saying The authors of the study wrote in the conclusion: "The findings of this study with over 25,800 participants provide robust evidence supporting extremely severe obesity specifically as a public health emergency. The association with metabolic and cardiovascular complications necessitates urgent public health action, such as early prevention, targeted education, and the mobilization of resources." What Happens Next? The authors called for "urgent public health interventions" and proposed a multi-layered approach, including preventive education, improved access to nutritious foods, and equitable health care.